VBC-103

N/A

Report date: 2026/04/14 20:00:15
First In Class

Base Information

Drug NameVBC-103
Drug Alias NameVBC-103VBC103VAC-103AVZO-103
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Trop-2Anti-NECTIN4
TargetsTumor-associated calcium signal transducer 2Nectin-4
Therapy Area/IndicationsSolid tumoursTriple Negative Breast NeoplasmsCarcinoma, Transitional Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesVelaVigo (Shanghai) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesVelaVigo Bio IncAvenzo Therapeutics IncVelaVigo (Shanghai) Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursTriple Negative Breast NeoplasmsCarcinoma, Transitional Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A